Metabolic Associated Fatty Liver Disease Increases the Risk of Systemic Complications and Mortality. A Meta-Analysis and Systematic Review of 12 620 736 Individuals

Change from NAFLD to MAFLD increases the awareness of fatty liver disease in primary care physicians and specialists

(2021) Yasser Fouad et al.   JOURNAL OF HEPATOLOGY

Therapeutic pipeline in nonalcoholic steatohepatitis

(2021) Raj Vuppalanchi et al.   Nature Reviews Gastroenterology & Hepatology

Outcomes of NAFLD and MAFLD: Results from a community-based, prospective cohort study

(2021) Madunil Anuk Niriella et al.   PLoS One

The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease

(2021) Yuemin Nan et al.   JOURNAL OF HEPATOLOGY

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

(2021) Matthew J Page et al.   BMJ-British Medical Journal

Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach

(2021) Giovanni Targher et al.   Lancet Gastroenterology & Hepatology

Cardiovascular and renal burdens of metabolic associated fatty liver disease from serial US national surveys, 1999–2016

(2021) Hao-Jie Zhang et al.   CHINESE MEDICAL JOURNAL

Metabolic dysfunction-associated fatty liver disease and mortality among Chinese adults: a prospective cohort study

(2021) Xiaomo Wang et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Association of MAFLD with diabetes, chronic kidney disease, and cardiovascular disease: a 4.6-year cohort study in China

(2021) Yebei Liang et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States

(2021) Donghee Kim et al.   JOURNAL OF HEPATOLOGY

The progression and regression of metabolic dysfunction-associated fatty liver disease are associated with the development of subclinical atherosclerosis: A prospective analysis

(2021) Shanshan Liu et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Risk stratification using sarcopenia status among subjects with metabolic dysfunction‐associated fatty liver disease

(2021) Ho Soo Chun et al.   Journal of Cachexia Sarcopenia and Muscle

Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases

(2021) Mohammed Eslam et al.   Lancet Gastroenterology & Hepatology

NAFLD or MAFLD: Which Has Closer Association With All-Cause and Cause-Specific Mortality?—Results From NHANES III

(2021) Qi Huang et al.   Frontiers in Medicine

Is Fatty Liver Associated With Depression? A Meta-Analysis and Systematic Review on the Prevalence, Risk Factors, and Outcomes of Depression and Non-alcoholic Fatty Liver Disease

(2021) Jieling Xiao et al.   Frontiers in Medicine

An Observational Data Meta-analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD

(2021) Grace En Hui Lim et al.   Clinical Gastroenterology and Hepatology

Metabolic Dysfunction-Associated Fatty Liver Disease Predicts Long-term Mortality and Cardiovascular Disease

(2021) Joon Ho Moon et al.   Gut and Liver

Metabolic-associated fatty liver disease and major adverse cardiac events in patients with chronic coronary syndrome: a matched case–control study

(2021) Hui-Hui Liu et al.   Hepatology International

Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan

(2021) Masato Yoneda et al.   JOURNAL OF GASTROENTEROLOGY

The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?

(2021) Jeffrey V. Lazarus et al.   JOURNAL OF HEPATOLOGY

Metabolic dysfunction–associated fatty liver disease and the risk of 24 specific cancers

(2021) Zhenqiu Liu et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Advancing the global public health agenda for NAFLD: a consensus statement

(2021) Jeffrey V. Lazarus et al.   Nature Reviews Gastroenterology & Hepatology

Metabolic associated fatty liver disease is a risk factor for chronic kidney disease

(2021) Yoshitaka Hashimoto et al.   Journal of Diabetes Investigation

Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis

(2021) Rohit Loomba et al.   GASTROENTEROLOGY

Nonalcoholic Fatty Liver Disease: What Does the Primary Care Physician Need to Know?

(2020) Jeffrey Budd et al.   AMERICAN JOURNAL OF MEDICINE

MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease

(2020) Mohammed Eslam et al.   GASTROENTEROLOGY

A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement

(2020) Mohammed Eslam et al.   JOURNAL OF HEPATOLOGY

From NAFLD to MAFLD: when pathophysiology succeeds

(2020) Herbert Tilg et al.   Nature Reviews Gastroenterology & Hepatology

The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease

(2020) Mohammed Eslam et al.   Hepatology International

Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study

(2020) Hokyou Lee et al.   Clinical Gastroenterology and Hepatology

MAFLD and risk of CKD

(2020) Dan-Qin Sun et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary

(2019) Donna K. Arnett et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Past, present and future perspectives in nonalcoholic fatty liver disease

(2019) Arun J. Sanyal   Nature Reviews Gastroenterology & Hepatology

Fixed and random effects models: making an informed choice

(2018) Andrew Bell et al.   QUALITY & QUANTITY

Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis

(2016) Giovanni Targher et al.   JOURNAL OF HEPATOLOGY

The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations

(2015) Brian Hutton et al.   ANNALS OF INTERNAL MEDICINE

Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range

(2015) Xiang Wan et al.   BMC Medical Research Methodology

The global NAFLD epidemic

(2013) Rohit Loomba et al.   Nature Reviews Gastroenterology & Hepatology

Chronic kidney disease

(2011) Andrew S Levey et al.   LANCET

Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: Is there a link?

(2010) Giovanni Targher et al.   JOURNAL OF HEPATOLOGY

Hospital-based comprehensive cardiac rehabilitation versus usual care among patients with congestive heart failure, ischemic heart disease, or high risk of ischemic heart disease: 12-Month results of a randomized clinical trial

(2008) Ann-Dorthe Olsen Zwisler et al.   AMERICAN HEART JOURNAL